• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SLNO Investigation: Investors Encouraged to Contact Kirby McInerney LLP

    1/9/26 6:00:00 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $SLNO alert in real time by email

    NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ:SLNO) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices.

    [LEARN MORE ABOUT THE INVESTIGATION]

    What Happened?

    On August 15, 2025, Scorpion Capital published a report that described Soleno's only product, Vykat XR, as overpriced and potentially unsafe for children. On this news, the price of Soleno shares declined by $5.73 per share, or approximately 7.41%, from $77.36 per share on August 14, 2025 to close at $71.64 on August 15, 2025.

    Then on November 4, 2025, Soleno revealed during its quarterly earnings call that the discontinuation rate of Vykat XR related to adverse effects was approximately 8% at the end of the third quarter of fiscal 2025. Soleno's Chief Executive Officer disclosed during the call that Soleno "did see a disruption in our [Vykat XR] launch trajectory in the wake of a short seller report that was released in mid-August [i.e, the Scorpion Capital report], mostly in the form of a lower number of start forms and increased discontinuations for non-serious adverse events. On this news, the price of Soleno shares declined by $16.98 per share, or approximately 26.59%, from $63.85 per share on November 4, 2025 to close at $46.87 on November 5, 2025.

    What Should I Do?

    If you purchased or otherwise acquired Soleno securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

    [LEARN MORE ABOUT SECURITES CLASS ACTIONS]

    Kirby McInerney LLP is a New York-based plaintiffs' law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm's efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP's website.

    This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

    Contacts

    Kirby McInerney LLP        

    Lauren Molinaro, Esq.

    212-699-1171

    https://www.kmllp.com

    https://securitiesleadplaintiff.com/

    investigations@kmllp.com



    Primary Logo

    Get the next $SLNO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SLNO

    DatePrice TargetRatingAnalyst
    11/18/2025$75.00Outperform
    Wolfe Research
    10/7/2025$125.00Buy
    Goldman
    8/20/2025$123.00Overweight
    Wells Fargo
    6/23/2025$110.00Buy
    TD Cowen
    3/5/2025$74.00Buy
    Stifel
    12/2/2024$74.00Buy
    Stifel
    12/2/2024$72.00Outperform
    Robert W. Baird
    9/3/2024$70.00Buy
    H.C. Wainwright
    More analyst ratings

    $SLNO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Manning Meredith

    4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)

    3/31/26 8:17:07 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Huang Michael F.

    4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)

    3/31/26 8:15:43 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CHIEF FINANCIAL OFFICER Fulk Jennifer was granted 39,200 shares (SEC Form 4)

    4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)

    3/4/26 5:59:56 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $SLNO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio

    VYKAT™ XR (diazoxide choline) is the First and Only FDA Approved Treatment for Hyperphagia in Prader-Willi Syndrome and Represents a Transformative Therapy Expands Neurocrine's High-Growth Commercial Portfolio to Three First-in-Class Medicines Including INGREZZA® (valbenazine) and CRENESSITY® (crinecerfont)Establishes a Durable Platform for Long-Term Revenue Growth and Value Creation, Supported by Strong VYKAT XR Intellectual Property Estate Expected to Extend into the mid-2040sNeurocrine to Host Conference Call at 8:00 AM ET Today to Discuss Transaction SAN DIEGO and REDWOOD CITY, Calif., April 6, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) and Soleno Therapeutics, Inc.

    4/6/26 7:00:00 AM ET
    $NBIX
    $SLNO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer

    REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Jennifer Fulk as Chief Financial Officer, succeeding James Mackaness, who announced that he will be retiring from the Company by the end of the first quarter. Mr. Mackaness will serve as a consultant to Soleno through the end of the year to ensure a smooth transition. Mrs. Fulk brings to Soleno more than two decades of public company experience in leading financial strategy, investor relations, financial reporting, and operational efficiency, with a diverse c

    2/26/26 8:00:00 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT™ XR

    REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2025 and provided an update on the U.S. launch of VYKAT™ XR (diazoxide choline) extended-release tablets. Fourth Quarter and Full-Year 2025 and Recent Corporate Highlights Revenue, net, from the sale of VYKAT XR for the three and twelve months ended December 31, 2025, was $91.7 million and $190.4 million, respectively.From approval on March 26, 2025 through December 31, 2025, Soleno reports: 1,250 patien

    2/25/26 4:01:00 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $SLNO
    SEC Filings

    View All

    SEC Form 8-K filed by Soleno Therapeutics Inc.

    8-K - SOLENO THERAPEUTICS INC (0001484565) (Filer)

    4/7/26 6:58:45 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC14D9C filed by Soleno Therapeutics Inc.

    SC14D9C - SOLENO THERAPEUTICS INC (0001484565) (Subject)

    4/6/26 5:17:37 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC TO-C filed by Soleno Therapeutics Inc.

    SC TO-C - SOLENO THERAPEUTICS INC (0001484565) (Subject)

    4/6/26 5:08:18 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $SLNO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Perceptive Advisors Llc bought $15,113,916 worth of shares (866,789 units at $17.44) (SEC Form 4)

    4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)

    9/28/23 3:45:22 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $SLNO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Soleno Therapeutics with a new price target

    Wolfe Research initiated coverage of Soleno Therapeutics with a rating of Outperform and set a new price target of $75.00

    11/18/25 8:27:59 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Goldman initiated coverage on Soleno Therapeutics with a new price target

    Goldman initiated coverage of Soleno Therapeutics with a rating of Buy and set a new price target of $125.00

    10/7/25 9:49:14 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Wells Fargo initiated coverage on Soleno Therapeutics with a new price target

    Wells Fargo initiated coverage of Soleno Therapeutics with a rating of Overweight and set a new price target of $123.00

    8/20/25 9:01:56 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $SLNO
    Financials

    Live finance-specific insights

    View All

    Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio

    VYKAT™ XR (diazoxide choline) is the First and Only FDA Approved Treatment for Hyperphagia in Prader-Willi Syndrome and Represents a Transformative Therapy Expands Neurocrine's High-Growth Commercial Portfolio to Three First-in-Class Medicines Including INGREZZA® (valbenazine) and CRENESSITY® (crinecerfont)Establishes a Durable Platform for Long-Term Revenue Growth and Value Creation, Supported by Strong VYKAT XR Intellectual Property Estate Expected to Extend into the mid-2040sNeurocrine to Host Conference Call at 8:00 AM ET Today to Discuss Transaction SAN DIEGO and REDWOOD CITY, Calif., April 6, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) and Soleno Therapeutics, Inc.

    4/6/26 7:00:00 AM ET
    $NBIX
    $SLNO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT™ XR

    REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2025 and provided an update on the U.S. launch of VYKAT™ XR (diazoxide choline) extended-release tablets. Fourth Quarter and Full-Year 2025 and Recent Corporate Highlights Revenue, net, from the sale of VYKAT XR for the three and twelve months ended December 31, 2025, was $91.7 million and $190.4 million, respectively.From approval on March 26, 2025 through December 31, 2025, Soleno reports: 1,250 patien

    2/25/26 4:01:00 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Soleno Therapeutics to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026, at 4:30 PM ET

    REDWOOD CITY, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its fourth quarter and full-year 2025 financial results, as well as operational highlights, after the close of the U.S. financial markets on Wednesday, February 25, 2026. The Company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Wednesday, February 25, 2026Time:4:30 PM Eastern TimeUnited States:1-800-717-1738Internation

    2/11/26 8:00:00 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $SLNO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Soleno Therapeutics Inc.

    SC 13D/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

    11/19/24 9:44:27 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13D/A filed by Soleno Therapeutics Inc.

    SC 13D/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

    11/14/24 4:30:58 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Soleno Therapeutics Inc.

    SC 13G/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

    11/14/24 12:51:18 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $SLNO
    Leadership Updates

    Live Leadership Updates

    View All

    Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer

    REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Jennifer Fulk as Chief Financial Officer, succeeding James Mackaness, who announced that he will be retiring from the Company by the end of the first quarter. Mr. Mackaness will serve as a consultant to Soleno through the end of the year to ensure a smooth transition. Mrs. Fulk brings to Soleno more than two decades of public company experience in leading financial strategy, investor relations, financial reporting, and operational efficiency, with a diverse c

    2/26/26 8:00:00 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Soleno Therapeutics Appoints Biopharmaceutical Executive Mark W. Hahn to its Board of Directors

    REDWOOD CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of biopharmaceutical finance veteran Mark W. Hahn as an independent director to its Board of Directors and a member of its Audit Committee. Mr. Hahn brings to Soleno's Board nearly 30 years of CFO-level experience and has played a key role in numerous successful product launches, financings, and M&A transactions within the life sciences sector. With the addition of Mr. Hahn, the Soleno Board increases to seven seats.    "I am very pleased to welcome Mark to the

    10/13/25 8:00:00 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Soleno Therapeutics Set to Join Russell 3000® Index

    REDWOOD CITY, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024. "Inclusion in the Russell indexes is a significant milestone and reflects the meaningful progress Soleno has made in advancing our lead candidate DCCR (diazoxide choline) extended-release ta

    6/4/24 8:00:00 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care